GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
Few predictive markers exist for response to adjuvant chemotherapy in breast cancer. The 78-kDa glucose-regulated protein (GRP78) is a potent antiapoptotic factor, conferring drug resistance. Recently, we reported that high GRP78 expression in breast cancer specimens predicts a shorter recurrence-free survival in patients who received doxorubicin-based adjuvant chemotherapy. Interestingly, the opposite effect was observed in 25 patients who additionally received a taxane. To confirm this potentially paradigm shifting finding, we investigated whether GRP78 is associated with recurrence-free survival in an independent cohort of taxane-treated breast cancer patients. Immunohistochemical staining of GRP78 was performed on archival paraffin-embedded formalin-fixed tumor specimens obtained from 48 female breast cancer patients before chemotherapy treatment. These patients received doxorubicin and cyclophosphamide, followed by paclitaxel or docetaxel on a clinical trial. GRP78 expression level was evaluated by a pathologist, masked to all clinical and outcome data. Association between GRP78 expression and recurrence-free survival was evaluated. GRP78 positivity predicts a better recurrence-free survival, independent of other prognostic factors [hazard ratio (HR) for moderate positivity: 0.40 (95% confidence interval (CI): 0.087-1.83); HR for strong positivity: 0.16 (95% CI: 0.018-1.50); p(trend) = 0.053]. In a pooled analysis with the previous 25 patients, almost identical HRs were obtained with p(trend) = 0.024. This provides further evidence that GRP78 is a potential independent predictor for response to taxane-based adjuvant chemotherapy in breast cancer.
Lee
Eunjung
E
Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 90089-9176, USA.
Nichols
Peter
P
Groshen
Susan
S
Spicer
Darcy
D
Lee
Amy S
AS
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000627:therapeutic use; D000091342:Endoplasmic Reticulum Chaperone BiP; D005260:Female; D006360:Heat-Shock Proteins / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011237:Predictive Value of Tests; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D015415:Biomarkers; D000091342:Endoplasmic Reticulum Chaperone BiP; C000717247:HSPA5 protein, human; D006360:Heat-Shock Proteins; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel
Cell. 1986 Jul 18;46(2):291-300
3087629
Cancer Res. 2007 Apr 15;67(8):3496-9
17440054
Mol Cancer Res. 2008 Aug;6(8):1268-75
18708359
Cancer Res. 2006 Sep 15;66(18):9260-9
16982771
Cancer Res. 2007 Apr 15;67(8):3734-40
17440086
Curr Mol Med. 2006 Feb;6(1):45-54
16472112
Ann Intern Med. 2008 Mar 4;148(5):358-69
18252678
Cancer Res. 2007 Oct 15;67(20):9809-16
17942911
N Engl J Med. 2007 Oct 11;357(15):1496-506
17928597
Nat Clin Pract Oncol. 2008 Oct;5(10):570-1
18762793
Cancer Res. 2006 Feb 1;66(3):1702-11
16452230
J Histochem Cytochem. 1997 Mar;45(3):327-43
9071315
J Biol Chem. 2003 Jun 6;278(23):20915-24
12665508
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004421
17943815
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Cancer. 2006 Jun 1;106(11):2337-44
16649217
Cancer Res. 2006 Aug 15;66(16):7849-53
16912156